Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00071396
Status:
COMPLETED
Last Update Posted:
2012-08-07
First Post:
2003-10-21
Brief Title:
Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders
Sponsor:
Organization:
MD Anderson Cancer Center